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Anticancer drugTo counteract genotoxic stress, DNA repair functions are in effect. Most of them are constitutively expressed
while some of them can be up-regulated depending on the level of DNA damage. In human cells, only few
DNA repair functions are subject of induction following DNA damage, and thus there is a need to identify
and characterize inducible repair functions more thoroughly. Here, we provide evidence that the “three
prime exonuclease I” (TREX1) is up-regulated in human ﬁbroblasts and cancer cells on mRNA and protein
level. Transcriptional upregulation of TREX1 was observed upon exposure to ultraviolet light and various an-
ticancer drugs in glioma and malignant melanoma cells. Induction of TREX1 was found following treatment
with the crosslinking alkylating agents nimustine, carmustine, fotemustine and the topoisomerase I inhibitor
topotecan, but not following temozolomide, etoposide and ionizing radiation. Induction of TREX1 following
DNA damage requires the AP-1 components c-Jun and c-Fos, as shown by siRNA knockdown, EMSA experi-
ments, ChIP analysis and reporter assays with the TREX1 promoter and constructs harboring mutations in
the AP-1 binding site. To analyze whether TREX1 expression impacts the sensitivity of cancer cells to thera-
peutics, TREX1 expression was down-regulated by siRNA in malignant glioma and melanoma cells. TREX1
knockdown resulted in enhanced cell death following nimustine, fotemustine and topotecan and to a reduced
recovery from the anticancer drug induced block to replication. The data revealed that induction of TREX1 is a
survival response evoked by various genotoxic anticancer drugs and identiﬁed TREX1 as a potential
therapeutic target for anticancer therapy.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The genome is perpetually under threat from exogenous genotoxic
stress, such as ultraviolet light and environmental compounds causing
DNA damage. To counteract this damage, DNA repair mechanisms
have evolved which repair the different DNA lesions (for review see
[1]). Apart from thewell-deﬁned role ofmost of the DNA repair proteins
that recognize speciﬁc lesions, several proteins like helicases or
nucleases have a less deﬁned role in DNA repair. One of these nucleases
is the three prime exonuclease I (TREX1, DNase III), which is a 3′–5′
exonuclease that catalyzes the excision of nucleoside monophosphates
from the 3′ termini of DNA [2]. It is active as a homodimer [3] that
prefers a partial duplex DNA with multiple mispaired 3′ termini.
Mutations in TREX1 are associated with the Aicardi–Goutières
syndrome [4,5], autosomal dominant retinal vasculopathy with
cerebral leukodystrophy [6], systemic lupus erythematosus [7] and
familial chilblain lupus [8]. In rodents, TREX1 knockout mice develop: +49 6131 178499.
ann).
l rights reserved.inﬂammatory myocarditis, resulting in progressive cardiomyopathy
causing circulatory failure and reduced survival [9]. Regarding its
involvement in the development of autoimmune disease, it has
been shown that TREX1 prevents the cell-intrinsic initiation of
autoimmunity via degradation of cytoplasmic ssDNA [10]. It was
also reported that failure to degrade genomic dsDNA is a principal
pathway of immune activation in TREX1 mediated autoimmune
diseases [11]. The most frequent mutations of TREX1 in familial
chilblain lupus and Aicardi–Goutières occur at amino acid positions
Asp-18 and Asp-200 and render TREX1 completely deﬁcient in
degrading dsDNA and reduce the efﬁciency of ssDNA degradation
[12]. Moreover, it was shown that TREX1 interacts with members of
the SET complex that plays a role in DNA degradation during
granzyme A-mediated cell death [13]. In line with the ﬁnding that
the SET complex also facilitates HIV-1 infection by preventing suicidal
autointegration of the virus [14] it was shown that TREX1 digests
non-integrated HIV DNA, thereby inhibiting the innate immune
response to HIV-1 infection [15].
Besides its role in the prevention of autoimmune reactions, it has
been suggested that TREX1 is involved in the cellular response to
DNA damage. TREX1 is mainly localized in the endoplasmic reticulum
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with ionizing radiation, hydroxyurea [16], ultraviolet (UVC) light or
benzo(a)pyrene diol epoxide (BPDE) [17]. This might indicate a
supporting role for TREX1 in the replication of damaged DNA, as
inferred from co-localization of TREX1 with BrdU [16] and from the
ﬁnding that TREX1 deﬁcient cells show a chronic activation of the
ATM-triggered DNA damage checkpoint [16]. We further showed
that trex1 mRNA and TREX1 protein are up-regulated following
exposure of mouse ﬁbroblasts to UVC light. This induction is due to
promoter activation and occurs via the AP-1 binding site 676 bp
upstream of the ATG start codon, which is recognized by c-Fos/AP-1.
The identiﬁcation of TREX1 as an inducible repair gene in mouse
ﬁbroblasts leads to the assumption that TREX1 is involved in the
DNA damage defense. In fact, TREX1 protects against UVC-induced
DNA damage as TREX1 knockout mouse cells are hypersensitive to
UVC light [17]. While the involvement of TREX1 in the cellular
response to genotoxins has been studied intensively in the mouse
system, only limited data is available as to the inducibility and role
of TREX1 in the genotoxic defense in human cells.
The purpose of the present study was to analyze the regulation of
TREX1 in normal (diploid) human ﬁbroblasts and cancer cells upon
exposure to genotoxic stress. We observed that in human ﬁbroblasts
as well as in glioma and malignant melanoma cells TREX1 is
up-regulated following genotoxic stress, with AP-1 being decisively
involved. Downregulation of TREX1 by siRNA provides evidence that
induction of TREX1 is a genotoxic stress response that mediates
killing resistance to UVC and chloroethylating and topoisomerase I
inhibiting anticancer drugs, which are highly effective in inducing
AP-1.
2. Experimental procedures
2.1. Cell lines
Human ﬁbroblasts (GM637, VH10tert), glioma cells (LN229) and
melanoma cells (D03 and D05) were described previously [17–19].
They were grown in Dulbecco's minimal essential medium (DMEM)
containing 10% fetal bovine serum (FBS), in 7% CO2 at 37 °C.
2.2. Treatment conditions
For UV light treatment, growth medium was aspirated and cells
were irradiated with UVC light (280 nm) at a dose rate of 1 J/m2/s
with a radium NSE 11-270 low pressure UV lamp (Philips). Thereafter
the medium was returned to the plates and cells were incubated at
37 °C for the indicated time points. For anticancer drug treatment,
fotemustine, ACNU or topotecan (provided by the pharmacy of the
University Medical Center, Mainz) was added directly to the medium.
2.3. Preparation of cell extracts and Western blot analysis
Whole cell extracts suitable for the detection of phosphorylated
proteins were prepared by direct lysis in 1× Roti-Load (Carl Roth
GmbH), separated by SDS-PAGE, electro-blotted onto nitrocellulose
membranes and incubated with speciﬁc antibodies (Suppl. Table 1).
All antibodies were diluted 1:1000 in 5% non-fat dry milk, 0.2%
Tween/TBS and incubated overnight at 4 °C. HRP conjugated
anti-rabbit (KCB003) and anti-mouse (KBC002) IgG antibodies were
diluted 1:3000 and incubated for 2 h at room temperature. The
protein–antibody complexes were visualized via ECL reaction.
2.4. Preparation of RNA, semi-quantitative PCR and real-time PCR
Total RNAwas isolated using the RNA II Isolation Kit (Machery and
Nagel, Düren, Germany). One μg RNA was transcribed into cDNA
(Verso cDNA Kit, Thermo Scientiﬁc, Bonn, Germany) in a volume of40 μl, and 3 μl was subjected to PCR performed by the use of speciﬁc
primers (MWG Biotechnology; Suppl. Table 2) and Red-Taq Ready
Mix (Sigma-Aldrich). Real-time PCR was performed using the
SensiMix™ SYBR Green & Fluorescein Kit (Bioline, London, UK) and
the CFX96 Real-Time System (Biorad, Hercules, USA).
2.5. Preparation of nuclear extracts and EMSA
Nuclear cell extractswere prepared and subjected to electromobility
shift assays (EMSA) or Western blot analysis as described previously
[20]. The sequence of the oligonucleotides speciﬁc for the AP-1 binding
site of the collagenase promoter was 5′-AGTGGTGACTCATCACT-3′ and
the oligonucleotide sequence speciﬁc for the AP-1 binding site of the
human trex1 promoter was 5′-GGAATTGTCCTGAGTCATTGCTTTG-3′.
For supershift experiments, 1 μg of antibodies speciﬁc for c-Fos (sc52)
and c-Jun (sc45) was pre-incubated with 4 μg protein extract for
30 min at room temperature.
2.6. Determination of apoptosis
For monitoring drug-induced apoptosis, ethanol-ﬁxed cells were
stained with propidium iodide (PI). The Sub-G1 fraction was
determined by ﬂow cytometry. The protocol was described previous-
ly [21,22]. Experiments were repeated at least three times, mean
values ± SD are shown and data were statistically analyzed using
Student's t test.
2.7. Knockdown using siRNA
Downregulation of TREX1 was achieved through the use of
speciﬁc siRNA (sense 5′-CCAAGACCAUCUGCUGUCA-3′, antisense
5′-UGACAGCAGAUGGUCUUGG-3′ [13]). Downregulation of c-Fos
and c-Jun was performed using the siRNA from Santa Cruz (sc29221
and sc29223). For transfection we used the Lipofectamine RNAiMAX
Transfection Kit (Invitrogen).
2.8. Immunoﬂuorescence
Cells were seeded on cover slips. Following genotoxin exposure,
cells were ﬁxed with methanol/acetone (3:1) (−20 °C, 5 min). A
second ﬁxation step was performed using 4% para-formaldehyde
(−20 °C, 15 min). Cells were then blocked in 5% BSA/PBS. The
antibodies were polyclonal anti-TREX1 (H00011277 D01P, Abnova)
and, as secondary antibody, Alexa Fluor 488 labeled anti-rabbit
(Invitrogen). Between all staining steps cells were washed 2 times
for 5 min with PBS and one time with PBS/4 M NaCl. Nuclear staining
was performed using TO-PRO-3 iodide (Invitrogen). Slides were
mounted in Vectrashield medium (Vector Laboratories Inc.) and
analyzed using a confocal laser scanningmicroscope (LSM 710, Zeiss).
2.9. BrdU assay
Cells were cultured in DMEM/10% FBS and, after exposure to
the given anticancer drug, the thymidine analog BrdU (10 μM) was
added to the medium. After a 1 h-incubation, the incorporation was
analyzed using Cell Proliferation ELISA bromodeoxyuridine colori-
metric assay (Roche Applied Sciences) in a microplate reader.
2.10. Chromatin immunoprecipitation assay (ChIP)
Chromatin immunoprecipitation was performed as described
previously [17]. In brief, LN229 and D03 cells were non-treated or
treated with the anticancer drug for 16 h, cellular genomic DNA and
proteins were crosslinked with 1% formaldehyde. Genomic DNA was
fragmented by soniﬁcation to a fragment size of 500 to 1500 bp and
subjected to immunoprecipitation (IP) using a c-Jun speciﬁc antibody
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binding site of trex1 (hTREX1-CHIP-up: CTTCTTCCTGTCCCTGGCTG,
hTREX1-CHIP low: CCAGTTTCCCAGGCTTTCCT); and as negative
control, β-actin speciﬁc primers (hActin-up: TCCGCTGCCCTGAGGCACTC,
hActin-low: GAGCCGCCGATCCACACGGA).
2.11. Measurement of hTREX1 promoter activity (Dual-Luciferase Assay)
The human TREX1 promoter was cloned into the vector pGL4. Site
directed mutagenesis of the AP-1 binding site was performed via the
QuickChange II XL site directed mutagenesis kit (Agilent Technology/
Stratagene) at two positions. The sequence of the whole promoter
and of the downstream luciferase gene was veriﬁed by sequencing
(Genterprise, Mainz, Germany). LN229 and D03 cells were exposed
to the given anticancer drugs for 2 h, thereafter the medium was
removed. 10 ml drug-free medium, which was pre-conditioned (by
parallel cultivation in a dish containing LN229 or D03 cells) to avoid
serum-effects, was added and the promoter constructs were
transfected into the cells using Effectene reagent (Qiagen). 24 h laterTime (h)con
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Fig. 1. UV light triggered induction of TREX1 in human ﬁbroblasts. (A) Exponentially grow
isolated and semi-quantitative PCR was performed using primers speciﬁc for trex1, c-fos and
(B) Exponentially growing VH10tert ﬁbroblasts were exposed to 20 J/m2 UV. Up to 24 h late
ies raised against TREX1, c-Fos, c-Jun and phosphorylated c-Jun. As loading control, ß-Actin s
for c-Jun (c-Jun-si) or non-silencing siRNA (ns-si). 24 and 48 h later, protein extracts were p
antibodies against c-Jun and phosphorylated c-Jun. (D) VH10tert ﬁbroblasts were transfecte
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c-Jun and c-Fos to the reaction. The speciﬁc binding of AP-1 is indicated by an arrow and tthe activity of the promoter was analyzed by measurement of ﬁreﬂy
and as transfection control Renilla Luciferase activity.
3. Results
3.1. Impact of c-Fos and c-Jun on the induction of human TREX1 following
UV irradiation
To analyze the role of AP-1 in the regulation of TREX1 following
genotoxin treatment, we compared the time-dependent induction
of TREX1 with the activation of c-Fos and c-Jun in VH10tert diploid
human ﬁbroblasts exposed to 20 J/m2 UV light. To this end, we
performed semi-quantitative PCR (Fig. 1A) and Western blot analysis
(Fig. 1B). The results show that the induction of trex1mRNA (starting
4 h after exposure) and TREX1 protein (starting 8 h after exposure)
preceded the induction of c-Fos protein (starting 16 h after
exposure), which indicates that c-Fos does not play a pivotal role in
the regulation of TREX1 in human ﬁbroblasts exposed to UV light.
Unlike c-Fos, c-Jun was activated by phosphorylation as early as 4 h4 8 16 24 Time (h)con
TREX1
cJun-Ser73
c-Fos
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c-jun
Time (h)
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*
ing VH10tert ﬁbroblasts were exposed to 20 J/m2 UV. Up to 16 h later, total RNA was
c-jun. As loading control, gapdh speciﬁc primers were used (con, non-exposed control).
r, total protein extracts were isolated. Immunodetection was performed using antibod-
peciﬁc antibody was used. (C) VH10tert ﬁbroblasts were transfected with siRNA speciﬁc
repared and subjected toWestern blot analysis. Immunodetection was performed using
d with siRNA speciﬁc for c-Jun (c-Jun-si) or non-silencing siRNA (ns-si). 24 h later, the
i-quantitative PCR using trex1 and c-jun speciﬁc primers (con, non-exposed cells). (E)
P-1) were incubated with nuclear extracts from VH10tert cells exposed to 20 J/m2 UV
rex1 AP-1 oligonucleotide was analyzed by the addition of speciﬁc antibodies against
he supershift (AP-1/antibody complex) by an asterisk.
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mRNA, compatible with the hypothesis that in human cells c-Jun is
involved in the induction of TREX1. This hypothesis was further
corroborated by down-regulation of c-Jun via speciﬁc siRNA. The
effectiveness of the knockdown is shown in Fig. 1C, demonstrating
approximately 90% reduction of both the non-phosphorylated and
phosphorylated c-Jun proteins 24 and 48 h after siRNA transfection.
To monitor the effects of siRNA transfection on phosphorylated
c-Jun protein, cells were exposed to 20 J/m2 UV 4 h prior to cell
harvest. We found that knockdown of c-Jun had a pronounced effect
on the expression of trex1 mRNA. Thus, in control siRNA (ns-siRNA)
transfected cells, UV light strongly induced trex1 mRNA expression
(determined 8 and 16 h post-UV) while trex1 induction was
completely abrogated after transfection with c-Jun speciﬁc siRNA
(Fig. 1D). To further substantiate the role of c-Jun in human TREX1
induction, we analyzed the AP-1 binding activity in nuclear extracts
of VH10tert cells by performing electromobility shift assays (EMSA),
using radio-labeled oligonucleotides harboring the AP-1 binding site
of the human trex1 promoter (htrex1 AP-1). The oligonucleotides
were incubated with nuclear extracts obtained from VH10tert cells,
collected at different times after exposure to 20 J/m2 UV light. As
shown in Fig. 1E, time-dependent induction of AP-1 binding activity
was observed, reaching its maximum 4 to 8 h after exposure. In
order to prove that c-Jun is a component of the AP-1 complex,
we performed supershift experiments 8 h after UV exposure; the
addition of a speciﬁc antibody against c-Jun, but not c-Fos, resulted
in a clear supershift (labeled by asterisk), providing further proof
that c-Jun, but not c-Fos, plays a key role in the induction of TREX1
in human ﬁbroblasts following UV-induced DNA damage.
To answer the question whether c-Fos is unable to trigger induc-
tion of human TREX1 or whether this is simply due to its delayed
induction, we assessed the sensitivity of human GM637 ﬁbroblasts
overexpressing c-Fos [23]. To this end we selected stably transfected
c-Fos clones displaying enhanced expression of c-fos mRNA and
c-Fos protein (clones B4 and B5) along with the parental GM637
cells and a clone (A2) not overexpressing c-Fos mRNA or protein
(Fig. 2A). Overexpression and nuclear accumulation of c-Fos were
veriﬁed by laser scanning microscopy (Fig. 2B). In spite of the
overexpression of c-Fos, the basal expression of trex1 mRNA
remained equal in all clones as shown by PCR (Fig. 2C). In contrast,
a slight difference was observed concerning the UVC provoked induc-
tion of trex1. In c-Fos overexpressing cells (clones B4 and B5) a more
pronounced induction of trex1 mRNA was observed 8 h after UV
exposure (Fig. 2D). To further substantiate the role of AP-1, EMSA
were performed, showing that also in GM637 cells UV exposure trig-
gered AP-1 activity (data not shown). To analyze the composition of
the AP-1 complex, supershift experiments were performed in
GM637 and c-Fos overexpressing GM637-B5 cells 8 and 16 h after
UV irradiation (Fig. 2E). In GM637 and GM637-B5 cells the TREX1
speciﬁc AP-1 site was recognized by c-Jun 8 and 16 h after UV expo-
sure. Interestingly, in both cell lines binding of c-Fos was detected
16 h after UV exposure; in GM637-B5 cells it occurred already 8 h
after exposure. The data indicate that c-Fos has the ability to bind to
the human TREX1 speciﬁc AP-1 binding site, but since c-Fos becomes
activated only at late time points in human ﬁbroblasts exposed to UV
light, it is substituted by other members of the AP-1 family.
3.2. Expression of trex1 in glioma cell lines and regulation by anticancer
drugs
In normal cells, theMAPK cascade and AP-1mediated signaling are
usually downregulated and only activated upon growth stimuli or
genotoxic stress. Mutations in genes involved in this pathway are
commonly found in tumor cells, leading to enhancedMAPK activation
and oncogenic stress. c-Fos is also expressed at variable levels in
different types of cancer [24,25]. Therefore, it is reasonable to positthat not only c-Fos but also its target genes including TREX1 are
expressed at variable levels in tumor cells. To this end, we monitored
the expression of TREX1 in tumor cell lines and observed a variable
amount of trex1mRNA in 16 glioma cell lines (Fig. 3A). The expression
was lowest in U118 and highest in LN308 glioma cells, with a
difference in the level of ≈15 fold. We further used the glioma cell
line LN229, showing an intermediate expression level, for the analysis
of TREX1 induction following anticancer drug treatment. Therefore
cells were exposed to nimustine (ACNU), carmustine (BCNU),
etoposide, topotecan (TPT) and temozolomide, which are drugs used
in the therapy of glioma, as well as ionizing irradiation (IR).
Induction of trex1 mRNA was observed upon exposure to the
chloroethylating nitrosoureas ACNU and BCNU and the topoisomerase
I inhibitor TPT, but not following treatment with the topoisomerase II
inhibitor etoposide, the methylating drug temozolomide and IR
(Fig. 3B). It thus appears that the induction of TREX1 is dependent
on the genotoxic drug applied, i.e. on the type of DNA damage induced
by the particular drug.
3.3. Role of c-Fos and c-Jun in the induction of TREX1 in glioma cells
exposed to TPT and ACNU
Similar to the experiments performed with ﬁbroblasts, we
compared the time-dependent induction of TREX1 with the activa-
tion of the AP-1 proteins c-Jun and c-Fos in LN229 glioma cells
exposed to 1 μg/ml TPT (Fig. 4A,B) or 50 μM ACNU (Fig. 4D,E).
Again semi-quantitative PCR (Fig. 4A,D) and Western blot analyses
were performed (Fig. 4B,E). The results show that TPT and ACNU trig-
gered induction of TREX1 on mRNA and protein level, which occurred
later than in UV-exposed ﬁbroblasts, i.e. 16 to 24 h after exposure. In
LN229 cells also the induction of c-Fos mRNA and protein reached its
maximum at this time point. C-Jun became activated by phosphoryla-
tion starting 8 h after ACNU and TPT exposure. Therefore, in LN229
cells exposed to TPT or ACNU, the TREX1 induction paralleled the
induction of c-Fos and followed the activation of c-Jun, which is
compatible with the hypothesis that both c-Fos and c-Jun are
involved. The involvement of AP-1 in the regulation of TREX1 was
veriﬁed by EMSA. Both anticancer drugs induced a time-dependent
induction of AP-1 binding activity using oligonucleotides harboring
the AP-1 binding site of the human trex1 promoter (Fig. 4C and F).
To further prove the requirement of AP-1 for the induction of
TREX1 following exposure to anticancer drugs, c-Jun or c-Fos
was down-regulated via speciﬁc siRNA; the effectiveness of the
knockdown is presented in Fig. 5A, showing nearly complete reduc-
tion of the c-Jun and c-Fos proteins 24 h after siRNA transfection.
Knockdown of both c-Jun and c-Fos clearly abrogated the induction
of trex1mRNA after ACNU or TPT treatment (Fig. 5B). As an additional
internal control for the transfection effectiveness, c-jun and c-fos
mRNA expression was determined in the same PCR experiment
(Fig. 5B). Since, contrary to ﬁbroblasts, in glioma cells c-Jun and
c-Fos seems to play an important role in the regulation of trex1, we an-
alyzed the composition of the AP-1 complex bound to the trex1 pro-
moter. Supershift experiments were performed in LN229 cells 16 h
after anticancer drug exposure. Both after ACNU and TPT treatment,
the TREX1 speciﬁc AP-1 site was recognized by c-Jun and c-Fos
(Fig. 5C). Obviously in LN229 cells treated with ACNU or TPT, both
c-Jun and c-Fos participate in the formation of the AP-1 complex
that is responsible for TREX1 induction.
As mentioned above, induction of TREX1 was not observed upon
temozolomide, etoposide and IR. It is reasonable to suppose that
these treatments do not trigger Fos and Jun induction to an extent
that is sufﬁcient to activate target genes. To prove this hypothesis
we exposed LN229 cells to equitoxic concentrations of the topoisom-
erase I inhibitor TPT, which is able to induce TREX1, and the
topoisomerase II inhibitor etoposide (Fig. 5D). Contrary to TPT,
etoposide was unable to activate the MAPK cascade, as indicated by
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Fig. 2. UV light triggered induction of TREX1 in human c-Fos overexpressing ﬁbroblasts. (A) Total RNA and protein extracts were prepared from GM637 ﬁbroblasts and GM637
clones stably overexpressing c-Fos and from a clone showing no overexpression of c-Fos and subjected to PCR (upper panel) or Western blot analysis (lower panel). The expression
of c-Fos was analyzed via c-Fos speciﬁc primers or antibodies. For loading control, gapdh or ß-Actin was detected. (B) GM637 and GM637-B5 cells were exposed to 10 J/m2 UV and
c-Fos was detected 16 h later by immunoﬂuorescence using laser scanning microscopy. (C) Total RNA was prepared from GM637 ﬁbroblasts and the different clones.
Semi-quantitative PCR was performed using primers speciﬁc for trex1 and as loading control, gapdh. (D) GM637 cells and the different clones were exposed to 10 J/m2 UVC.
Total RNA was isolated at different time points after exposure and quantitative real-time PCR was performed using trex1 speciﬁc primers (loading control, gapdh; con, unexposed
control). (E) GM637 and c-Fos overexpressing GM637-B5 cells were exposed to 10 J/m2 UV light for 8 or 16 h and nuclear extracts were subjected to EMSA. For supershift assay,
binding of the human trex1 AP-1 oligonucleotide was analyzed by the addition of speciﬁc antibodies against c-Jun and c-Fos to the reaction. The speciﬁc binding of AP-1 is indicated
by an arrow and the supershift (AP-1/antibody complex) by an asterisk.
1836 M.T. Tomicic et al. / Biochimica et Biophysica Acta 1833 (2013) 1832–1843its inability to induce c-fos mRNA expression (Fig. 5E) and AP-1
activation (Fig. 5F). The data suggest that different DNA lesions
induced by these drugs are responsible for the differences in their
potency of inducing TREX1.
3.4. c-Fos and c-Jun in the induction of TREX1 in human melanoma cells
To elucidate whether induction of TREX1 following anticancer
drugs is a common mechanism in cancer cells, we conducted
experiments with melanoma cells exposed to fotemustine, a
chloroethylating drug used in the treatment of this type of cancer
[26], which acts similar to ACNU. As shown in Sup. Fig. 1A, trex1
mRNA was variably expressed in melanoma cell lines. Induction of
TREX1 was observed in D03 melanoma cells on mRNA and protein
level (Fig. 6A,B). Fotemustine-provoked induction of TREX1 was
accompanied by induction and activation of c-Fos and c-Jun (Fig. 6A,B) and by increase in AP-1 binding activity (Fig. 6C). Again
down-regulation of c-Jun and c-Fos by siRNA (Fig. 6D) abrogated
the induction of trex1 mRNA following fotemustine treatment
(Fig. 6E). Interestingly, in another melanoma cell line (D05) no
induction of TREX1 (Sup. Fig. 1B) was detected. At the same time
neither induction of c-Fos (Sup. Fig. 1C) nor increase in AP-1 activity
(Sup. Fig. 1D) was observed following fotemustine treatment. In
addition, also UV light failed to activate AP-1 binding activity (Sup.
Fig. 1E) and phosphorylation of JNK in D05 cells (Sup. Fig. 1F).
Obviously, in this cell line alterations in the MAPK pathway have
occurred that rendered them non-responsive.
To further prove that TREX1 is regulated in human tumor cells by
anticancer drugs via the AP-1 binding site, the human trex1 (htrex1)
promoter was cloned and subjected to the Dual Luciferase Reporter
Assay (for promoter sequence see Sup. Fig. 2). We also performed
site-directed mutagenesis in order to inactivate the AP-1 binding
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construct was activated in LN229 cells by ACNU and TPT and, in D03
cells, by fotemustine, no induction was observed using the promoter
construct carrying the mutated AP-1 binding site. Furthermore, ChIP
analysis was performed using c-Jun speciﬁc antibody. Similar to
EMSA and promoter activity studies, exposure of human tumor cell
lines LN229 and D03 to ACNU, TPT and fotemustine induced binding
of c-Jun to the endogenous htrex1 promoter (Fig. 7B).
3.5. Cellular localization of TREX1
In non-exposed mouse ﬁbroblasts the TREX1 protein is localized
exclusively in the cytoplasm. A translocation into the nucleus was
observed only in genotoxin-exposed cells [16,17]. This suggests that
TREX1 participates in DNA repair, which requires nuclear localization.
To elucidate whether TREX1 can also be found in the nucleus of
human cells, we analyzed the intracellular localization of TREX1 in
human ﬁbroblasts, LN229 glioma and D03 melanoma cells. Similarto mouse, TREX1 was localized in unexposed human ﬁbroblasts
predominantly in the cytoplasm and the nuclear expression increased
upon UV exposure (Sup. Fig. 3A). Contrary to normal ﬁbroblasts, in
LN229 and D03 tumor cells TREX1 was already found at high amount
in the nucleus of untreated cells and no nuclear translocation was
observed following treatment with ACNU, TPT or fotemustine (Sup.
Fig. 3A and data not shown).
3.6. Impact of TREX1 on the sensitivity of glioma and melanoma cells to
anticancer drugs
An important question to be addressed is whether human TREX1
induction has an impact on the sensitivity of cancer cells to anticancer
drugs. To this end, TREX1 was down-regulated in LN229 glioma and
D03 malignant melanoma cells through siRNA transfection. The
efﬁciency of siRNA-mediated down-regulation is shown in Fig. 8A.
Survival assays showed that knockdown of TREX1 ameliorated the
killing response to anticancer drugs. Thus, in LN229 cells, a signiﬁcant
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to fotemustine (Fig. 8C). Similar to mouse ﬁbroblasts, also a strong
sensitization to UV light was observed in human ﬁbroblasts upon
knockdown of TREX1 (Sup. Fig. 3B,C). To obtain further insight in
the molecular mechanism of TREX1 mediated protection against
anticancer drugs, we determined the impact of TREX1 on DNA
synthesis. The replication arrest induced by anticancer drugs upon
siRNA mediated knockdown of TREX1 was analyzed using the BrdU
incorporation assay. As shown in Fig. 8D, 24 and 48 h after treatment
with ACNU, TPT or fotemustine a signiﬁcant reduction of DNA synthe-
sis was observed in TREX1-siRNA compared to ns-siRNA transfected
cells. The data indicate an involvement of TREX1 in processes that
abrogate the replication arrest following genotoxic stress brought
about by anticancer drugs.
4. Discussion
The regulation of TREX1 has previously been analyzed in murine
ﬁbroblasts. It was shown that TREX1 is regulated on transcriptional
level by UV light, which requires the AP-1 component c-Fos [17]. A
transcriptional induction of TREX1 was also observed in murine
macrophages upon IFN-γ treatment, where the regulation occurred
via c-Jun/AP-1 without the involvement of c-Fos [27]. Whether andhow TREX1 is regulated in human cells has not yet been demonstrated.
Another important question to be answered is whether TREX1 becomes
up-regulated in tumor cells and whether this impacts tumor cell
sensitivity to anticancer drugs. Up to now only one report addressed
this question and showed that TREX1 was regulated by camptothecin
and doxocycline in nasopharyngeal carcinoma; the mechanism
underlying the regulation remained unclear [28]. Here, we investigated
the regulation of TREX1 in human ﬁbroblasts uponUVC exposure and in
human glioma andmalignantmelanoma cells upon treatmentwith var-
ious anticancer drugs that are being used in the therapy of these types of
cancer. The experiments revealed an induction of TREX1 following
ACNU, BCNU, fotemustine and TPT, but not upon temozolomide,
etoposide and IR. The agent speciﬁcity could be explained by the
different DNA lesions induced and the ability of the particular exposure
to activate the Fos/Jun-triggered MAPK pathway. While UV light and
the chloroethylating nitrosoureas ACNU, BCNU and fotemustine induce
bulky DNA lesions that interfere with the transcription and replication
machinery, IR induces directly DNA double-strand breaks (DSB) and
temozolomide induces DNA methylations that result in DSB formation
[29,30]. Although direct evidence is lacking, it is reasonable to conclude
that replication fork arrest provides a stronger signal for AP-1 induction
than DSB. In linewith this, induction of c-Fos and activation of JNKwere
only observed upon exposure of cells to extremely high doses of IR
c-Fos
ns
siRNAcon
c-Fos
siRNA
c-Jun
siRNA
A
c-Jun
-sicon ns-si
c-Fos
-si
ß-Actin
c-Jun
con
ACNU 
concon
TPT B
c-Jun
-si ns-si
c-Fos
-si
c-fos
c-jun
trex1
c-fos
c-jun
trex1
gapdh
c-Jun
Abcon
c-Fos
Ab
c-Jun
Abcon
c-Fos
Ab
LN229-TPTLN229-ACNUC
gapdh
*
E
trex1
Time (h)conD 50
etoposide
gapdh
Time (h)con
c-fos
2 2
9-
et
op
os
id
e
0
10
20
30
40 topotecan
Su
b-
G
1 
(%
)
c-jun
gapdh
LN
2
8 16 24 48
0 0.5 1 1.5 2 2.5
Anticancer drug (µg/ml)
Time (h)
8 16 24 48
con 8 16 24 con 8 16 24F
col AP-1 htrex1 AP-1
Fig. 5. Impact of c-Fos and c-Jun on anticancer drug triggered induction of TREX1 in human glioma cells. (A) LN229 glioma cells were transfected with siRNA speciﬁc for c-Jun
(c-Jun-si), c-Fos (c-Fos-si) or non-silencing siRNA (ns-si). 24 h later, protein extracts were prepared and subjected to Western blot analysis. Immunodetection was performed
using antibodies against c-Jun and c-Fos (loading control, ß-Actin). (B) LN229 cells were transfected with siRNA speciﬁc for c-Jun, c-Fos or non-silencing siRNA. 24 h later, the
cells were exposed to 50 μM ACNU (left panel) or 1 μg/ml TPT (right panel). RNA was isolated 16 h later and subjected to semi-quantitative PCR using c-fos, c-jun and trex1 speciﬁc
primers (loading control, gapdh; con, non-exposed cells). (C) EMSA supershift assay. LN229 cells were exposed to 50 μM ACNU or 1 μg/ml TPT for 16 h. Composition of the AP-1
factor bound to the human trex1 AP-1 oligonucleotide was analyzed by the addition of speciﬁc antibodies against c-Jun and c-Fos to generate supershift reaction. (D) LN229
cells were exposed to different doses of TPT or etoposide and incubated for 96 h. Cells were stained with PI and the sub-G1 fraction was determined by ﬂow cytometry. (E)
LN229 glioma cells were exposed to 1 μg/ml etoposide. Up to 48 h later, total RNA was isolated and semi-quantitative PCR was performed using primers speciﬁc for trex1, c-fos
and c-jun. (F) Oligonucleotides containing either the AP-1 binding site of the collagenase promoter (col AP-1) or the AP-1 binding sites of the human trex1 promoter (htrex1
AP-1) were incubated with nuclear extracts from LN229 cells exposed to 1 μg/ml etoposide for 8, 16 or 24 h and subjected to EMSA.
1839M.T. Tomicic et al. / Biochimica et Biophysica Acta 1833 (2013) 1832–1843(>100 Gy, [31,32]) or of themethylating agent MNNG (>70 μM; [33]).
In accordance with this our data showing that the topoisomerase I
inhibitor TPT, which generates DNA single-strand breaks by trapping
the enzyme–DNA–cleavage complexes [34,35] and mediates cytotoxic-
ity via blockage of transcription and replication [36], but not the
topoisomerase II inhibitor etoposide, which directly generates DSB, is
able to increase c-Fos expression and to enhance AP-1 activity.
Contrary to the results obtained in mouse ﬁbroblasts, the UVC
mediated induction of TREX1 in human ﬁbroblasts seems to be
independent of c-Fos. This is explained on the basis of the ﬁnding
that c-Fos is immediate–early induced in mouse, but not human
cells upon UVC exposure [23]. In human cells, the UVC mediatedinduction of c-Fos was delayed and occurred after the induction of
TREX1. Here the induction is mediated mostly by the AP-1 compo-
nent c-Jun, which is immediately activated upon genotoxic exposure
by phosphorylation via JNK. In line with the notion that c-Jun is
decisively involved in TREX1 regulation in human cells are the
ﬁndings that c-Jun binds to the TREX1 speciﬁc AP-1 site, and that
knockdown of c-Jun abrogates the UVC mediated induction of TREX1.
In glioma LN229 cells exposed to ACNU or TPT and in melanoma
D03 cells exposed to fotemustine the expression of TREX1 was
enhanced on RNA and protein level. Under these conditions, the
induction of c-Fos and c-Jun phosphorylation paralleled the induction
of TREX1. In tumor cells, siRNA mediated knockdown of both c-Jun
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c-Jun to the TREX1 speciﬁc AP-1 site was observed in vitro via
EMSA and binding of c-Jun was observed in vivo via ChIP analysis
indicating that TREX1 is regulated in human tumor cells by AP-1
following exposure to anticancer drugs. The impact of AP-1 on the
induction of TREX1 in human cells treated with anticancer drugs
was further assessed in promoter studies. The human TREX1 promot-
er was cloned and its inducibility was analyzed in reporter assays in
ACNU, TPT and fotemustine treated cells. All three agents induced
activation of the human TREX1 promoter, and this induction was
abrogated by mutational inactivation of the AP-1 binding site.
In mouse ﬁbroblasts TREX1 was shown to be localized mainly in
the endoplasmic reticulum and translocated into the nucleus upon
IR, hydroxyurea [16] and UVC exposure [17]. It was also reported
that TREX1 translocates into the nucleus during granzyme A mediat-
ed cell death [13]. Here we show that TREX1 translocates into the
nucleus in human ﬁbroblasts upon UVC exposure. It is interesting
that TREX1 is already strongly expressed in the nucleus of tumor
cells, which leads to the assumption that in tumor cell lines the
mechanism responsible for the cytoplasmic localization of TREX1 is
altered or that signals are present, constantly increasing the nuclear
translocation of TREX1 even without exposure to genotoxic stress.
Nevertheless, these data clearly suggest a nuclear function for
TREX1 besides its well-established role in the degradation of
cytoplasmic ssDNA [10]. This nuclear function of TREX1 in response
to genotoxic stress appears to be dependent on the type of DNA
damage. Thus TREX1 knockout mouse embryonic ﬁbroblasts are
protected against IR [16], but more sensitive to UVC [17]. The datapresented here show that also in human cells TREX1 protects against
UVC induced cell death. Further, we extend the protective role
of TREX1 to anticancer drugs forming crosslinking adducts (the
chloroethylating nitrosoureas) and topoisomerase I inhibitors (TPT).
For TPT [36], UVC [37] and crosslink-inducing anticancer drugs
[38,39] cytotoxicity is associated with the blockage of DNA replica-
tion. In this context, it is important to note that a delayed recovery
from the block to replication was observed in TREX1 knockout
mouse ﬁbroblasts [17]. A functional involvement of TREX1 in replica-
tion of damaged DNA was suggested by the fact that TREX1
co-localizes with BrdU in IR- and hydroxyurea-exposed rodent cells
[16]. Also in human cells TREX1 seems to be associated with replica-
tion. Thus, DNA synthesis was clearly reduced in glioma and
malignant melanoma cells treated with anticancer drugs.
The molecular mechanisms underlying the protective role of
TREX1 on genotoxic stress induced by UVC or anticancer drugs are
still unclear. A possible explanation could be that TREX1 is responsi-
ble for the degradation of single-stranded DNA arising from the
processing of blocked replication forks. A combined action of FEN1,
DNA2 and TREX1 to degrade speciﬁc structures arising at stalled rep-
lication forks was previously suggested [16]. These structures could
be generated by combined helicase/endonuclease activity of enzymes
present at the replication fork, such as helicase/endonuclease DNA2
and the ﬂap endonuclease 1 (FEN1), which cooperate during the pro-
cessing of Okazaki fragments. In vitro, DNA2 can produce 50 nucleo-
tide long ssDNA ﬂaps that are substrates for FEN1 [40–42]. ssDNA
polynucleotides released by this process still contain the 5′ RNA prim-
er and require both a DNA 3′–5′ exonuclease and a ribonuclease
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1841M.T. Tomicic et al. / Biochimica et Biophysica Acta 1833 (2013) 1832–1843activity for their degradation. Interestingly, the Aicardi–Goutières
syndrome is characterized by mutations in any of the genes encoding
the three subunits of RNaseH2 [43], which represents the major
RNaseH activity hydrolyzing the RNA strand of an RNA:DNA hybrid
[44,45]. The importance of this mechanism conducting removal of ri-
bonucleotides from the DNA is further supported by the ﬁnding that
RNaseH2 null mice embryos show increased genomic instability
[46]. Recent results show that TREX1 is also involved in degradation
of dsDNA. Thus TREX1 locates at 3′ termini generated by endonucle-
ases and degrades the nicked DNA [11]. This activity is strongly re-
duced in mutated TREX1 that harbors alterations observed in
familial chilblain lupus and Aicardi–Goutières [47,48]. Whether
TREX1 can also degrade nicked DNA during DNA repair is not known.
Overall, the available data support the hypothesis that TREX1
is responsible for the degradation of aberrant DNA structures
arising during the processing of blocked DNA replication forks. As
TREX1 has endonuclease activity, an “above the normal level” in the
nucleus might be deleterious for the cell. Thus, it is reasonable to
conclude that a ﬁne-tuned system of transcriptional up-regulation
and nuclear translocation following DNA damage has been evolved
as part of the genotoxic defense system of the cell. The ﬁnding
that down-regulation of TREX1 sensitizes glioma and malignant mel-
anoma cells indicates that induction of TREX1 is a pro-survivalfunction. This pertains to genotoxic agents that are able to induce
AP-1 efﬁciently, while drugs like temozolomide and IR that are
weak inducers of Fos/Jun/AP-1 do not provoke the response. The
established role of TREX1 in the cellular defense makes it a potential
therapeutic target for anticancer therapy.Funding
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